Karyopharm Therapeutics, a clinical-stage biotech developing treatments for cancer and other major diseases, announced terms for its IPO on Monday. The Natick, MA-based company plans to raise $85 million by offering 5.7 million shares at a price range of $14 to $16. At the midpoint of the proposed range, Karyopharm Therapeutics would command a market value of $414 million.
Karyopharm Therapeutics, which was founded in 2008, plans to list on the NASDAQ under the symbol KPTI. Karyopharm Therapeutics initially filed confidentially on September 5, 2013. BofA Merrill Lynch and Leerink Swann are the joint bookrunners on the deal.
